MKI67 and breast carcinoma: Supporting this, a clinical trial correlated 18F-ISO-1 uptake in vivo with Ki-67 in ER+ breast cancer (39), notably the same IHC subset in which the correlation between σ2R/TMEM97 and proliferation is the strongest and the same subset in which the association with early relapse is the highest.